Muscle-invasive Bladder Cancer: How to Select Patients for Neoadjuvant Chemotherapy
UroCancer Clinics of India · 2024
DOI: 10.4103/ucci.ucci_16_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift UroCancer Clinics of India, 2024. Verfasst von Eunice Yun Xing und 1 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Approximately 25% of patients with bladder cancer present with muscle-invasive disease. International guidelines recommend cisplatin-based neoadjuvant chemotherapy (NAC) for patients suitable for radical treatment. However, appropriate candidate selection for NAC is crucial to ensure that the benefits outweigh potential toxicities and delays to radical cystectomy (RC). Patients should meet eligibility criteria for cisplatin therapy, and factors such as age, comorbidities, and nutritional status should be evaluated in conjunction. Timely initiation of NAC following diagnosis is essential. The use of NAC for T2 tumors and variant histology remains contentious. It is important to recognize that disease often undergoes upstaging post-RC, and variant histologies are associated with more aggressive clinical courses. These factors necessitate an individualized assessment to determine the appropriateness of NAC. Although biomarkers are not yet routinely used, they may play a pivotal role in optimizing patient selection for NAC in the near future.
Zitieren
APA
Xing, E. Y., & Sarwar, N. (2024). Muscle-invasive Bladder Cancer: How to Select Patients for Neoadjuvant Chemotherapy. UroCancer Clinics of India. https://doi.org/10.4103/ucci.ucci_16_24
Vancouver
Xing EY, Sarwar N. Muscle-invasive Bladder Cancer: How to Select Patients for Neoadjuvant Chemotherapy. UroCancer Clinics of India. 2024. doi:10.4103/ucci.ucci_16_24
BibTeX
@article{Xing2024,
author = {Xing, Eunice Yun and Sarwar, Naveed},
title = {Muscle-invasive Bladder Cancer: How to Select Patients for Neoadjuvant Chemotherapy},
journal = {UroCancer Clinics of India},
year = {2024},
doi = {10.4103/ucci.ucci_16_24}
}
EUVIMED